basal insulin
Long-Acting Basaglar and the New Era of “Biosimilar” Insulin
What you need to know about the new insulin, its cost, dosing, and beyond!
Xultophy Beats Out Lantus in Major Clinical Trial
One of the biggest drug highlights at the 2015 ADA Scientific Sessions was a compelling presentation by diaTribe scientific Advisory Board member Dr. John Buse on brand new phase 3 clinical trial data comparing Xultophy (a GLP-1 agonist/long acting insulin combination taken as a single injection) to Lantus (a long acting insulin) for the treatment of type 2 diabetes. The results of the 26-week study were very impressive...
A Potential Game-Changer in Type 2 Diabetes: GLP-1 Agonist/ Basal Insulin Combinations?
Our deep dive on a new therapy now available in Europe – the benefits, risks, and when it might come to the US.
Tresiba Launches in the US – Next Generation Once-Daily Basal Insulin
Flat insulin allows for flexible dosing with lower likelihood of hypoglycemia. How is it priced vs. Levemir?
FDA Approves New Insulin Glargine Basaglar – The First “Biosimilar” Insulin in the US
Will this drug be cheaper than Lantus and other insulins?
Lilly Discontinues Development of Liver-Selective Basal Insulin Peglispro
What were the risks and benefits of this drug?